Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 2/20 | 0.39 |
| ▸ | TPX2 | Q9ULW0 | 2/20 | 0.39 |
| ▸ | EIF4E | P06730 | 1/20 | 0.39 |
| ▸ | FASN | P49327 | 3/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenol SCHEMBL18587050 | 0.94 | DHODH (0.41) | CTSSCTSKSCN9ADHODHAURKA | |
| SCHEMBL18587305 | 0.86 | ERN1 (0.47) | SCN9AFASNMAPT | |
| SCHEMBL29587703 | 0.86 | TAF1 (0.46) | MAPTKDM4E | |
| SCHEMBL18586735 | 0.86 | ERN1 (0.47) | — | |
| SCHEMBL29588054 | 0.86 | ERN1 (0.47) | — | |
| SCHEMBL18617405 | 0.86 | TAF1 (0.46) | MAPTKDM4E | |
| SCHEMBL18587263 | 0.80 | XDH (0.43) | CTSSCTSKSCN9AFASNMAOA | |
| SCHEMBL18587347 | 0.78 | MAOA (0.53) | FASNMAOAMAOBKDM4E | |
| SCHEMBL18587254 | 0.78 | HPGD (0.56) | KDM4E | |
| SCHEMBL29588105 | 0.78 | HPGD (0.56) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352330-B2 | Phenoxymethyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11352330-B2 | Phenoxymethyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2022-06-07 | — | — | US | disclosed |
| CN-108026077-B | Phenoxymethyl derivatives | 豪夫迈·罗氏有限公司 | 2021-11-05 | — | — | CN | disclosed |
| US-20200339522-A1 | PHENOXYMETHYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-20200339522-A1 | PHENOXYMETHYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-29 | — | — | US | disclosed |
| EP-3344619-B1 | PHENOXYMETHYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-10-28 | — | — | EP | disclosed |
| EP-3344619-B1 | PHENOXYMETHYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-10-28 | — | — | EP | disclosed |
| US-10640472-B2 | Phenoxymethyl derivatives | HOFFMAN-LA ROCHE INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-10640472-B2 | Phenoxymethyl derivatives | HOFFMAN-LA ROCHE INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20180201588-A1 | PHENOXYMETHYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180201588-A1 | PHENOXYMETHYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180201588-A1 | PHENOXYMETHYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-07-19 | — | — | US | disclosed |
| EP-3344619-A1 | PHENOXYMETHYL DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2018-07-11 | — | — | EP | disclosed |
| WO-2017037146-A1 | PHENOXYMETHYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-03-09 | — | — | WO | disclosed |
| WO-2017037146-A1 | PHENOXYMETHYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339522-A1 | PHENOXYMETHYL DERIVATIVES | CNKSR1, RB1, RCOR1 | CTSS 2938/4885CTSK 2289/4885SCN9A 4486/4885 |
| US-10640472-B2 | Phenoxymethyl derivatives | CNKSR1, RB1, RCOR1 | CTSS 2938/4885CTSK 2289/4885SCN9A 4486/4885 |
| US-20180201588-A1 | PHENOXYMETHYL DERIVATIVES | CNKSR1, RB1, RCOR1 | CTSS 2938/4885CTSK 2289/4885SCN9A 4486/4885 |
| US-11352330-B2 | Phenoxymethyl derivatives | CNKSR1, RB1, RCOR1 | CTSS 2938/4885CTSK 2289/4885SCN9A 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.